A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaResearch in context

Summary: Background: Sarcomas represent an extensive group of malignant diseases affecting mesodermal tissues. Among sarcomas, the clinical management of chondrosarcomas remains a complex challenge, as high-grade tumours do not respond to current therapies. Mutations in the isocitrate dehydrogenase...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Verónica Rey, Juan Tornín, Juan Jose Alba-Linares, Cristina Robledo, Dzohara Murillo, Aida Rodríguez, Borja Gallego, Carmen Huergo, Cristina Viera, Alejandro Braña, Aurora Astudillo, Dominique Heymann, Karoly Szuhai, Judith V.M.G. Bovée, Agustín F. Fernández, Mario F. Fraga, Javier Alonso, René Rodríguez
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2024-04-01
Saila:	EBioMedicine
Gaiak:	Chondrosarcoma Enasidenib IDH2 Patient-derived models Personalized medicine
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2352396424001257
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!